Literature DB >> 8167493

Management of carcinomas of the upper gastrointestinal tract.

P Ellis1, D Cunningham.   

Abstract

Patients with oesophageal, gastric, and pancreatic carcinomas present a common and difficult problem for the clinician. Surgery is the best option for curative treatment but overall survival figures remain low. Recent improvements in our understanding of the biology of these tumours and improvements in their clinical staging, along with the development of combined modality approaches to local-regional disease, have led to renewed optimism that survival figures may be improved. This is particularly so for oesophageal and gastric carcinomas. In addition, there have been advances in the palliative management of all three tumours. This article examines some of these developments and looks at future prospects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8167493      PMCID: PMC2540003          DOI: 10.1136/bmj.308.6932.834

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  30 in total

1.  Bone turnover during high dose inhaled corticosteroid treatment.

Authors:  N J Ali; S Capewell; M J Ward
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

2.  Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

Authors:  C N Mallinson; M O Rake; J B Cocking; C A Fox; M T Cwynarski; B L Diffey; G A Jackson; J Hanley; V J Wass
Journal:  Br Med J       Date:  1980-12-13

3.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Authors:  J A Wils; H O Klein; D J Wagener; H Bleiberg; H Reis; F Korsten; T Conroy; M Fickers; S Leyvraz; M Buyse
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

Review 4.  Pylorus preserving pancreatoduodenectomy: an overview.

Authors:  P A Grace; H A Pitt; W P Longmire
Journal:  Br J Surg       Date:  1990-09       Impact factor: 6.939

5.  Unexpected side-effects of inhaled steroids: a case report.

Authors:  K Priftis; M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

6.  Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients.

Authors:  J J Grau; J Estapé; F Alcobendas; C Pera; M Daniels; J Terés
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

7.  Helicobacter pylori infection and the risk of gastric carcinoma.

Authors:  J Parsonnet; G D Friedman; D P Vandersteen; Y Chang; J H Vogelman; N Orentreich; R K Sibley
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

8.  Growth of asthmatic children during treatment with budesonide: a double blind trial.

Authors:  O D Wolthers; S Pedersen
Journal:  BMJ       Date:  1991-07-20

9.  A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.

Authors:  N K Kim; Y S Park; D S Heo; C Suh; S Y Kim; K C Park; Y K Kang; D B Shin; H T Kim; H J Kim
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

10.  Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.

Authors:  A M Murad; F F Santiago; A Petroianu; P R Rocha; M A Rodrigues; M Rausch
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

View more
  8 in total

1.  Cancer of the upper gastrointestinal tract. Palliative chemotherapy unproved in advanced gastric cancer.

Authors:  I Kunkler
Journal:  BMJ       Date:  1994-06-04

2.  Rethinking breast cancer screening strategies in resource-limited settings.

Authors:  M Galukande; E Kiguli-Malwadde
Journal:  Afr Health Sci       Date:  2010-03       Impact factor: 0.927

3.  Management of oesophageal cancer.

Authors:  J G Weil; S J Munday
Journal:  BMJ       Date:  1994-04-23

4.  Surgery for pancreatic cancer.

Authors:  R M Charnley; R C Spiller; J Doran
Journal:  BMJ       Date:  1994-06-25

5.  Quality of life measurement in patients with oesophageal cancer.

Authors:  J M Blazeby; M H Williams; S T Brookes; D Alderson; J R Farndon
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

6.  Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.

Authors:  C M Barton; N R Lemoine
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

7.  Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.

Authors:  A Bamias; D Cunningham; V Nicolson; A Norman; M Hill; M Nicolson; M O'Brien; A Webb; A Hill
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

8.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Authors:  S Pyrhönen; T Kuitunen; P Nyandoto; M Kouri
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.